Clinical trial
Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
NCT02630030 is registered in ClinicalTrials.gov with Emory University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
- Lead sponsor
- Emory University
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 24, 2016
- Completion date
- September 3, 2020
- Enrollment
- 3 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.